Browse Conditions Browse Medicines

NICE publish a draft guidance update in the diagnosis, monitoring and management of chronic asthma

For Asthma and Asthma (eosinophilic)

The National Institute for Health and Care Excellence (NICE) have published their latest update of guidance on the diagnosis, monitoring and management of chronic asthma.

The guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.

Who is it for?
  • People with suspected or diagnosed asthma, their families and carers
  • GPs and practice nurses
  • Healthcare professionals in secondary care and tertiary asthma services
  • Commissioners and providers
This guideline will update NICE guideline NG80 published in November 2017.

The consultation will end on 27th November 2019.

NICE have reviewed the evidence on increasing the dose of inhaled corticosteroids within a self-management programme in children and young people with asthma.

Interested parties are invited to comment on the new and updated recommendations.

People have the right to be involved in discussions and make informed decisions about their care.

Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines,
standards and laws (including on consent and mental capacity), and safeguarding.

© NICE [2019]

Asthma: diagnosis, monitoring and chronic asthma management. In development [GID-NG10143]. Expected publication date: 12 February 2020
Available from: See Link below. All rights reserved. Subject to Notice of rights
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

The information provided by NICE was accurate at the time this article was issued.

NICE draft guidance on asthma

Reporting of suspected adverse reactions

Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.

About Asthma About Asthma (eosinophilic)